AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab
An AstraZeneca unit can keep exclusively selling a cancer treatment combining two enzyme blockers, after an appellate board rejected a rival's claims that its ability to reduce common side effects in...To view the full article, register now.
Already a subscriber? Click here to view full article